Basic Information
EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML
INJECTION, SOLUTION
Regulatory Information
SIN16208P
May 27, 2021
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 4, 2025
XM05BX06
Company Information
Active Ingredients
Strength: 105 mg/1.17 mL
Detailed Information
Contraindications
**4.3 Contraindications** Hypocalcaemia EVENITY is contraindicated in patients with uncorrected hypocalcaemia \[see Special Warnings and Precautions for Use (4.4), Adverse Reactions (4.8), and Special Populations (4.6) – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_\]. Hypersensitivity EVENITY is contraindicated in patients with known clinically significant hypersensitivity to romosozumab or to any component of the product formulation \[see Special Warnings and Precautions for Use (4.4) and List of Excipients (6.1) – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_\]. Myocardial Infarction and Stroke EVENITY is contraindicated in patients with a history of myocardial infarction or stroke \[see Special Warnings and Precautions for Use (4.4) – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_\].
Indication Information
**4.1 Therapeutic Indications** Postmenopausal Osteoporosis EVENITY is indicated for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.